A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine

Summary

The purpose of this study is to learn about the safety effects of the Lyme disease vaccine (called VLA15), and its ability to protect people from Lyme disease after a 5th dose of the vaccine. This study is seeking participants who: are generally healthy and 7 years of age and older, have already been vaccinated with 4 doses of VLA15 (from the VALOR study), and have blood sample taken post dose 4. are not currently taking, or haven't recently taken, medicines like chemotherapy, blood products, or blood thinners.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Lyme Disease

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

7 years and older

Sex

All

Healthy volunteers

Accepted

Sponsor

Pfizer

Last updated on ClinicalTrials.gov

May 6, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites